Threat for increased medication

Just a few years ago, a little-known drug called Ozempic – previously used only to treat diabetes – emerged as a promising recent drug for weight management.

The Food and Drug Administration of the Administrative Agency Approval of Ozempic in 2021 for weight reduction treatment ushered in a brand new era for the category of medication that was called Glucagon-like peptide-1 agonistsor GLP-1.

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have turn into household names and key tools within the fight against obesity: 1 in 8 American adults Say they used a GLP-1 drug, and projections show that by 2030, 1 in 10 Americans are more likely to with these medications.

Research from my lab and others now suggests that GLP-1 drugs could also treat dozens of other ailments, including cognitive problems and addiction problems. However, my colleagues and I also found previously unidentified risks.

I’m a Physician Scientist And I lead a clinical epidemiology center that addresses essentially the most pressing public health issues. My team is working to handle critical knowledge gaps about Covid-19, Long Covid, influenza, vaccines, effectiveness and risks of common medicines, and way more.

On January 20, 2025, my team published a study of greater than 2.4 million individuals who evaluated the risks and advantages of GLP-1 drugs over 175 possible health outcomes. We found that these drugs reduced the danger of 42 health outcomes, nearly 1 / 4 of the entire we analyzed. These include neurocognitive disorders similar to Alzheimer's disease and dementia, substance use and addiction disorders, coagulation disorders, and a number of other other medical conditions.

Unfortunately, we also found that GLP-1 drugs carry significant unwanted side effects and increase the danger of 19 health conditions we studied, similar to: B. Gastrointestinal problems, kidney stones and Acute pancreatitisthrough which the pancreas becomes inflamed and dysfunctional.

https://www.youtube.com/watch?v=npyvr_2_rj4

Cognitive advantages

One of the important thing health advantages was that the GLP-1 drugs reduced the danger of neurodegenerative disorders, including Alzheimer's disease and dementia. These results are consistent with other research, including evidence from preclinical studies, showing that these drugs may reduce inflammation within the brain and improve the brain's ability to form and strengthen connections between its cells, thereby improving the way in which how they convey with one another. These effects help reduce cognitive decline.

Two other key studies have shown Patients treated with a GLP-1 drug for diabetes had a lower risk of dementia.

All of those studies strongly suggest a possible therapeutic use of GLP-1 drugs within the treatment of cognitive decline. Ongoing randomized trials—the gold standard for evaluating recent drug uses—are examining the results of GLP-1 drugs in early Alzheimer's disease, with results expected later in 2025.

Curb addiction and suicidal thoughts

GLP-1 medications have also shown potential for reducing the risks of several substance use disorders similar to alcoholPresent tobaccoCannabis, opioids and stimulants. This could also be attributable to the flexibility of those medications to modulate reward pathways, impulse control, and inflammatory processes within the brain.

The effectiveness of GLP-1 drugs in curbing addictive behavior may explain their spectacular success in treating obesity, a chronic disease state that many have suggested is actually a food addiction disorder.

Our study showed a reduced risk of suicidal ideation and self-harm in people using GLP-1 medication. This finding is especially significant Previous reports of suicidal thoughts and self-harm In people using GLP-1 drugs. In response to those reports, the European Medicines Agency conducted a review of all available data and concluded that it existed No evidence of an increased risk of suicide In people using GLP-1 drugs.

Now at the least two studies, including our own, show that GLP-1 drugs actually do Reduce the danger of suicide.

Other advantages

In addition to the well-documented effects of GLP-1 drugs in reducing the risks of undesirable cardiovascular And Kidney resultsOur study shows a major effect on reducing the danger of blood clotting, deep vein thrombosis and pulmonary embolism.

A puzzling finding in our study is the reduced risk of infectious diseases similar to pneumonia and sepsis. Our data complement one other recent study that reached an analogous conclusion cardiovascular death and death from infectious causesespecially Covid-19.

This is especially vital as Covid-19 is taken into account to be significant cardiovascular risk factor. Whether GLP-1 drugs fully offset the increased risk of heart problems related to CoVID-19 must be thoroughly evaluated.

GLP-1 drugs might also be useful in Fatty liver disease treatment and conditions from asthma to chronic obstructive pulmonary diseasesleep apnea, OsteoarthritisDepression and eye disorders.

https://www.youtube.com/watch?v=sygijtbx2xs

Risks and challenges

Despite their broad therapeutic potential, GLP-1 drugs will not be without risks.

Gastrointestinal problems similar to nausea, vomiting, constipation and constipation and gastroesophageal reflux disease are amongst essentially the most common opposed effects related to GLP-1 drugs.

Our study also identified other risks, including low blood pressure, sleep problems, headaches, kidney stone formation, and Gallbladder disease and diseases related to the bile ducts. We also saw an increased risk of drug-induced inflammation of the kidneys and pancreas – each serious conditions that may result in long-term health problems. These results highlight the importance of careful monitoring in people taking GLP-1 drugs.

A big challenge in the usage of GLP-1 drugs is the high rates at which patients stop usingoften driven by their exorbitant costs or the occurrence of opposed effects. Stopping can result in rapid weight gain.

This is an issue because obesity is a chronic disease. GLP-1 drugs provide effective treatment but don’t address the underlying causes of obesity and metabolic dysfunction. As a result, GLP-1 drugs should be taken long-term to take care of their effectiveness and stop rebound weight gain.

In addition, many questions remain concerning the long-term effectiveness and risks of those drugs, in addition to whether there are differences between GLP-1 formulations. Answering these questions is critical to guiding clinical practice.

The Latest in Health Technology: Nearly 80% of doctors who use telemedicine achieve this weekly, a study shows

DALLAS – Weight-loss drugs like Ozempic and Wegovy are gaining popularity amongst adults, who’re turning to the brand new drugs as a substitute for the standard – and infrequently ineffective – advice to “eat less and exercise more.”

As the drugs generally known as GLP-1 receptor agonists have gained a fame amongst adults, they’ve change into so is becoming increasingly popular amongst children and young people.

Um every fifth child Obesity exists within the United States, based on the U.S. Centers for Disease Control and Prevention. And prescriptions of GLP-1 have also skyrocketed amongst young people. More than 30,000 young people According to a University of Michigan study, 12- to 17-year-olds used GLP-1 in 2023.

Doctors say early intervention for obesity will help prevent later health problems, but prescribing medication to growing children also brings its own complications.

Dr. Chris Straughn, a pediatrician at Medical City Children's Hospital in Dallas, said research shows that GLP-1 may be each effective and protected for youngsters and adolescents, but that this research only shows the effect over just a few years.

“For both children and adults, we simply don’t know. These drugs are so new that we need more time,” Straughn said.

Wegovy, the burden loss equivalent drug Ozempic, is approved by the FDA to be used in children ages 12 and older. It shouldn’t be approved for youngsters under 12, although research continues to be ongoing on younger children. A recent study on Saxenda, a predecessor of Wegovy, found that the drug was effective in children ages 6 to 12.

This style of study is encouraging for using GLP-1 in children.

“Early intervention is a good thing, and that’s what pediatricians place a lot of emphasis on,” Straughn said. “So this can certainly be a tool.”

But there are still many unknowns.

Dr. Dan Cooper – a researcher and pediatrics professor on the University of California, Irvine's School of Medicine – said there are circumstances through which a GLP-1 prescription is sensible, akin to if a toddler is developing or has already developed diabetes. However, for other children the danger calculation is harder.

This is especially because there shouldn’t be much research on the long-term effects of GLP-1 when prescription begins in childhood or adolescence. Cooper said puberty is a very essential time for establishing long-term health, and never providing children's bodies and brains with the nutrients they need for correct development can have long-term effects.

“During this time, there is bone mineralization, muscle building, and likely changes in your brain and behavior related to energy balance,” Cooper said. “When you’re a young adult or older, you can’t do that again.”

It shouldn’t be clear whether GLP-1 use in childhood or adolescence could affect long-term development. And that's exactly what Cooper is all about.

“What is the long-term effect? Nobody knows. So my concern is that we should be very, very careful in using these drugs,” Cooper said.

Overall, Cooper says, parents shouldn't be afraid to ask their children's doctors about GLP-1, they usually shouldn't be afraid of their children taking the medication — when appropriate. For children and adolescents who begin taking GLP-1, Cooper said parents needs to be careful that it doesn’t trigger or worsen depressive symptoms of their child. He also said parents should proceed to encourage healthy eating habits and an energetic lifestyle.

Cooper had one other message for fogeys with obese or obese children: They and their children shouldn’t be ashamed.

“No one should be ashamed of this. People become obese because of our biology,” Cooper said. “Parents should understand that they should not blame themselves and that they should not blame their children for being overweight.”

©2024 The Dallas Morning News. Distributed by Tribune Content Agency, LLC.

Originally published: December 12, 2024 at 12:21 PM PST

Cost is an important think about coverage

Access to weight reduction is an issue

In just a couple of years, brand-name injectable medications comparable to Ozempic, Wegovy, Mounjaro and Zepbound have skyrocketed to fame Billion dollar annual sales for weight reduction in addition to controlling blood sugar levels and reducing the danger of heart disease.

But the worth of those injections is high: they cost about $800-$1,000 per 30 daysand when used alone for weight reduction, they are usually not covered by most insurance firms. Both medications mimic the naturally occurring hormone GLP-1 to control blood sugar and reduce food cravings. They can only be taken with a health care provider's prescription.

The Food and Drug Administration announced an official shortage of energetic ingredients in these drugs in 2022, but on October 2, 2024, the agency announced that this is able to be the case The shortage of the drug tirzepatide has been resolvedthe energetic ingredient in Mounjaro and Zepbound.

Despite the increasing demand and limited supply of those medications, no generic versions can be found. This is because of the patents for semaglutide – the energetic ingredient in Ozempic and Wegovy, which remains to be briefly supply – and tirzepatide won’t expire until 2033 and 2036respectively.

As a result, Non-branded alternatives Medicines, available with or with no prescription, flood the market. Still, these products pose real risks for consumers.

I’m a pharmacist Who is investigating weaknesses in federal supervision? recipe and over-the-counter medications And Dietary supplements within the USA My research group recently investigated loopholes which enable alternative products for weight reduction to enter the market.

High demand is driving GLP-1 wannabes newbies

The complement market is attempting to capitalize on GLP-1 demand with pills, teas, extracts and all types of other products claim to provide similar effects just like the brand names at a less expensive price.

Products containing the herb berberine only provide a a couple of kilos of weight reductionwhile many contain weight reduction supplements Stimulants comparable to sibutramine and laxatives comparable to phenolphthaleinthat increase the danger Heart attacks, strokes And Cancer.

The role of compounding pharmacies

Unlike the dietary supplements disguised as GLP-1 weight reduction products, pharmacies that manufacture supplements can produce customized versions of products that contain the identical energetic ingredients as the unique for patients who for some reason are neither branded nor Can use generic products.

These pharmacies may produce alternative versions of brand-name medications when official drug shortages exist.

Because demand for GLP-1 drugs far exceeds supply, compounding pharmacies legally produce a drug Variety of various semaglutide and tirzepatide products.

These products may are available different versions than those offered by brand manufacturers, comparable to vials containing powder that have to be dissolved in liquid, or as tablets or nasal spray.

Just like with brand name medications, you will have a legitimate prescription to acquire one. The prices range from $250 to $400 per 30 days – still a high price for a lot of consumers.

Compounding pharmacies must comply FDA sterility and quality production methodsbut these rules are usually not as strict for compounding pharmacies as they’re for business manufacturers of generic drugs.

In addition, the products that pharmacies produce are manufactured don’t must be tested on humans on safety or effectiveness, as is the case with branded products.

Even with compounded drug forms, getting the proper dosage is usually a challenge.

Companies using the system

For individuals who can't afford a compounded pharmacy product or can't get a legitimate prescription for semaglutide or tirzepatide, opportunistic corporations are stepping in to fill the gap. These include “peptide companies,” manufacturers that produce non-FDA-approved copycat versions of the drugs.

From November 2023 to March 2024, my team conducted a study to evaluate which of those peptide corporations were selling semaglutide or tirzepatide products. We searched the web for these peptide corporations and gathered details about what they sell and what their sales practices are.

We found that peptide sellers a Loophole for the sale of those drugs. On their web sites, the businesses state that their drugs are “for research use only” or “not for human consumption,” but they do nothing to confirm that the buyers are researchers or that the product is meant a research institution goes.

Reading the comment sections on company web sites and targeted ads on social media, it's clear that each buyers and sellers understand the farce. Unlike drug pharmacies, these peptide sellers don’t provide the materials you want to dissolve and inject the drug, don’t provide instructions, and typically don’t answer questions.

Because peptide sellers supposedly don’t sell to consumers, they don’t require a legitimate prescription and sell consumers the quantity of medication they want to buy. Even if an individual has an eating disorder, comparable to: Anorexia nervosaThe corporations are completely satisfied to sell you a semaglutide or tirzepatide product with no prescription. The average prices of those peptide products range from $181 to $203 per 30 days.

Base regulations

Peptide sellers would not have to stick to the principles or regulations that drug manufacturers or compounding pharmacies follow. Many corporations claim that their products are 99% pure, but a independent investigation of three corporations Products from August 2023 to March 2024 revealed that the purity of the products was far lower than promised.

A product contained endotoxin – a toxic substance produced by bacteria – suggesting it was contaminated with microbes. Additionally, the products' promised dosages were reduced by 29 to 39%. Poor purity may cause discomfort to patients Fever, chills, nauseaSkin irritation, infections and low blood pressure.

In this study, some corporations didn't ship the drug in any respect and told buyers they might must pay an extra fee to get the product through customs.

If a consumer is is broken by an inferior productit could be difficult to sue the vendor because the products specifically state that they’re “not intended for human consumption.” Ultimately, consumers are tricked into spending money on products which will never arrive, could cause an infection, may not have the proper dosage, and will not contain instructions on safely use or store the product.

Will prices for branded products fall?

To combat these alternative sellers, pharmaceutical company Eli Lilly began offering an alternate version of his brand name Zepbound Weight loss product in September 2024.

Instead of traditional injection pens, which cost greater than $1,000 a month to provide, this product is available in vials that the patient picks up and injects themselves. For patients taking 5 milligrams of Zepbound each week, the vial products would cost $549 per 30 days if patients purchase it through the corporate's online pharmacy and might prove they would not have insurance coverage for the drug.

After one Grilling on Capitol Hill In September 2024, the pharmaceutical company Novo Nordisk got here under intense pressure to supply patients without prescription insurance a less expensive product for its brand name Wegovy.

Additional brand-name drugs containing GLP-1 agonists are expected to come back onto the market in the following few years. As of October 2024, a A handful of those products are in late-stage clinical trialswith energetic ingredients comparable to Retatrutid, Survive And Ecnoglutideand greater than 18 other drug candidates are in earlier stages of development.

As latest pharmaceutical corporations enter this market, they have to offer patients lower prices than Eli Lilly and Novo Nordisk to be able to gain market share. This is the most definitely medium-term solution to scale back the fee of GLP-1 drugs and eliminate drug shortages in the marketplace.

PHILADELPHIA — Julia O'Reilly was 5-foot-2, 190 kilos, suffered from prediabetes and hypertension. Her only real exercise was chasing her little ones.

She met together with her doctors, who prescribed weekly Ozempic injections for O'Reilly. She lost 22 kilos.

But without the load, her face became saggy, her cheeks sunken and dark circles formed under her eyes, O'Reilly said.

“The goal was to lose weight,” O'Reilly said, “not to look gaunt and sickly.”

Those who take medications like Ozempic – whether for medical or aesthetic reasons – often find that weight reduction ends in what’s now called the “Ozempic face.” The result: Medical spas are seeing a rise in inquiries from clients who use medications like Ozempic, Wegovy, Mounjaro and Zepbound.

“I didn't want to radically change myself,” O'Reilly said. “But I wanted my face to match this better version of myself.”

After consultation with the medical and cosmetic team at Center City Med Spa Skin Care Clinic Body+Beauty Laboratoryshe decided that fillers were the perfect solution to restore the youthful fullness that she felt Ozempic had robbed her face of.

An old treatment for a brand new problem

According to a Gallup poll 6% of adults within the US, or 15.5 million peoplereport using drugs like Ozempic and Wegovy to drop a few pounds. When they work as hoped, doctors say they curb appetite and cravings. The downside: lack of muscle mass, which ends up in an aged face.

“It’s a protein problem,” explains Dr. Marc Neff, medical director at Jefferson Health New Jersey's Weight Loss Surgery Program. “Protein is important for skin elasticity, muscle tone and overall skin health. It's really important that people who start taking these medications work with a nutritionist to keep protein levels high.”

Aestheticians have been using synthetic hyaluronic acid fillers—Restylane, Juvéderm, Sculptra, Belotero—to plump and hydrate aging skin for greater than 20 years. When synthetic hyaluronic acid is injected into cheekbones, jawlines and under the eyes, it mimics the natural version—Mother Nature's secret to dewy, fresh-looking skin.

The regular injections have also helped cancer and HIV patients gain more self-confidence.

Over the years, nonetheless, fillers have come under the identical scrutiny as weight-loss drugs. Too much of them can result in a fake-looking face – see any reality TV star – not to say bruising, itching and swelling. And then there's the unfair pressure to all the time look young: the very proven fact that they exist sends the message to those that select to not have fillers that aging is just not an option, when in fact it's our only viable selection.

For patients who’ve lost weight with the brand new drugs, it will probably also seem to be they’re making an inconceivable pact with the evil beauty gods, or an unwinnable game. For many, it’s a game they’re comfortable to play.

“I deal with this topic every week,” said Sarah Sidiqian aesthetic nurse who sees about three “Ozempic Face” patients per week at Body+Beauty Laboratoryin comparison with once a month before weight-loss drugs became popular. “They all want to restore lost facial volume.”

A $4,000 solution

Before Linda Weller, 67, began using Mounjaro, her face looked pretty good for her age, she said. But after she lost 60 kilos in a 12 months, it began to “look like a landslide” — regardless that her A1C dropped and she or he was in a position to stop taking her blood pressure medication.

“I didn't want to spend money on a facelift,” Weller said. “So I got my cheeks done.”

“I look great and feel great,” Weller said.

Candice Reid, registered nurse and owner of a Mount Airy Med Spa Nurse Candiesaid she can be using more injectable hyaluronic acid, especially on clients over 40 who’ve lost weight.

In addition to the hyaluronic injections, Reid injects platelet-rich plasma or PRPinto clients' cheeks and jawline to stimulate collagen growth. Collagen is some of the necessary proteins our bodies produce to stop skin sagging. Production slows down as we enter our 30s and drops dramatically in our 40s.

“You can't see where you're going to lose weight,” Reid said. “But you can add volume to the areas of your face that have been affected by fat loss.”

On a recent Monday afternoon, O'Reilly was able to perk up. Five syringes of Restylane — greater than $4,000 in total — sat on the doctor's counter. After Sidiqi cleaned and numbed O'Reilly's face, he injected Restylane into each of O'Reilly's temples to provide her contour and under each of her cheekbones to lift her. Sidiqi injected Restylane into O'Reilly's chin to round it out, after which she had her lips plumped up, but not an excessive amount of, since the exaggerated pout is out.

The dark circles under her eyes were gone. The unwanted emaciation was gone. In lower than an hour, O'Reilly had her younger face back. The results should last a couple of 12 months.

“I like the way I look,” O'Reilly said. “I'm very happy.”

Will O'Reilly come back? She's undecided. Looking young isn't low-cost. Like weight-loss drugs, fillers may have to be an everyday a part of her beauty routine if she wants to maintain her looks. She's only 35.

©2024 The Philadelphia Inquirer, LLC. Visit www.inquirer.com. Distributed by Tribune Content Agency, LLC.

By Arthur Allen, KFF Health News

On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a number one Danish newspaper, urging the Danish company to live as much as its altruistic standards and lower U.S. prices for its successful diabetes and weight-loss drugs.

What Sanders didn't know was that Denmark, a rustic of six million people, was fighting its own crisis over the financing of Novo Nordisk's drugs Ozempic and Wegovy.

Most other developed countries, including Denmark, negotiate drug costs for his or her residents and pay prices which might be a fraction of those within the United States. But if a drug is effective and expensive, pharmaceutical corporations can clamp down on pricing. And Novo Nordisk did so, not less than initially, pushing the Danish health care system to its limits.

The country's public health system had adopted Ozempic as a diabetes drug for years, but in 2022 doctors began prescribing it for weight reduction as well, and shortly “they emptied all the coffers of the entire public health system,” said Jens Juul Holst, a professor on the University of Copenhagen and co-inventor of the drug.

Countries all over the world are fighting how and when to pay for Ozempic, Eli Lilly's Mounjaro and other drugs in the identical chemical class, especially when prescribed for weight reduction. In fact, the astronomically high prices within the U.S. set a bar that pharmaceutical corporations can use of their negotiations with other health systems.

In Denmark, where prescriptions for these drugs will devour 18 percent of the regional pharmaceutical budget in 2023, officials considered the unthinkable in a system that prides itself on free cradle-to-grave care: forcing patients to pay for Ozempic—a drug manufactured within the country—out of their very own pockets.

In America, stricter insurance policies are making it increasingly difficult for patients to acquire the medications, which may cost as much as $1,350 a month.

“In our clinic, there are month-to-month changes in terms of care, coverage and available drugs,” said Michael Blaha, director of clinical research on the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. He said doctors and patients play “a constant game of prior authorizations and appeals.”

The use of the drugs for weight reduction is a very sensitive issue. Novo Nordisk and Lilly are fighting for reimbursement – backed by some doctors and patient groups, lots of whom are funded by the drug corporations. They are pushing to overturn a 2005 federal regulation that prohibits Medicare from reimbursing weight-loss treatments.

“There's a strong likelihood that Medicare will cover these obesity drugs sooner or later,” said David Kim, an assistant professor of drugs and public health on the University of Chicago. If Medicare pays, he added, private insurers will likely follow suit.

The impact on government and personal insurance budgets, he said, depends upon three unanswered questions: How many individuals will ultimately get the drugs? How long will they take them? And at what cost?

The potential Medicare market alone is big. In 2020, about 13.7 million Medicare beneficiaries, a few quarter of the entire, were diagnosed as obese or obese, in keeping with Juliette Cubanski and Tricia Neuman, researchers at KFF, a nonprofit health information organization that features KFF Health News. Assuming a 50% discount on Wegovy's $1,300 monthly list price, that involves $107 billion. The total federal share of Medicare Part D spending in 2024 has been estimated at $120 billion.

Novo Nordisk has spent $7.6 million lobbying Congress over the past 12 months, and lobbying disclosures show that the vast majority of that cash was used to push bills within the House and Senate to expand the usage of GLP-1 drugs.

The pressure from pharmaceutical corporations is relentless. Pfizer, which has a GLP-1 drug in development, commissioned a white paper from the consulting firm Manatt arguing that Medicare law already allows coverage of those obesity drugs because they provide advantages beyond weight reduction. Novo and other pharmaceutical corporations have funded studies showing that taking these drugs results in savings in health look after chronic diseases.

But the Congressional Budget Office, whose estimates of the prices of such measures are crucial as to whether they’re ultimately implemented, has not yet issued a final statement. In a presentation in March, the office said it was “not aware of any empirical evidence directly linking the use of obesity drugs to reductions in other health care spending.”

Prime Therapeutics, a pharmacy reimbursement manager whose clients are employers that sponsor drug plans, released a study this 12 months that found that only a 3rd of patients who take a GLP-1 drug take it for a full 12 months. That means getting insurance firms to cover the drugs can sometimes be a waste of cash, said Patrick Gleason, chief research officer at Prime Therapeutics, because research shows that patients are likely to regain weight after stopping the drugs.

This does not likely surprise Danish scientist Holst. He says that for many individuals, appetite suppression through GLP-1 drugs is “so miserably boring that they can no longer stand it and have to go back to their old lives.”

One answer could possibly be weight reduction programs that use GLP-1 for a 12 months, for instance, followed by maintenance therapy with cheaper drugs, Kim says.

Either way, many experts in the sector say it is sensible to start out shedding weight before obesity-related chronic diseases equivalent to type 2 diabetes develop.

Because obesity is related to so many comorbidities, pharmaceutical manufacturers are currently conducting studies showing that GLP-1 drugs even have a positive effect on conditions equivalent to sleep apnea and heart, liver and kidney disease.

But even those that support the usage of these drugs acknowledge that there’s uncertainty about how long it takes for the health-promoting effects to take effect and whether shorter-term use can prevent or alleviate longer-term illnesses.

“Modeling the impact is complicated,” says Alison Sexton Ward, a researcher on the Schaeffer Center for Health Policy and Economics on the University of Southern California. “Medical costs will not fall immediately. The diseases prevented may not appear for years.”

Starting next 12 months, out-of-pocket costs for Part D Medicare enrollees can be capped at $2,000, meaning U.S. taxpayers could have to cover most Medicare drug costs. So it's no surprise that the Congressional Budget Office expects the administration to start Medicare price negotiations for semaglutide under the Inflation Reduction Act “within the next few years,” in keeping with its March presentation.

Under the terms of the law, Ozempic could possibly be subject to cost negotiations by the federal government as early as next 12 months, with recent prices taking effect in 2027. The negotiated unit price would apply to all types of the drug – Ozempic, its higher-dose weight-loss version Wegovy, and a pill called Rybelsus.

It is unclear how high the worth can be. Wegovy costs patients in Denmark as much as $365 a month, which normally doesn’t cover the fee of the drug – and about 140 $ in Germany and $92 within the UK

Meanwhile, generic drugmakers are preparing to sell their versions of semaglutide, that are expected to hit the market in China and Brazil as early as 2026. In the U.S., Americans will likely must wait until not less than 2032 because of patent restrictions within the U.S. The Federal Trade Commission has sought to shorten the drugs' exclusivity periods by difficult Novo Nordisk's patent applications for applicators used to inject the drugs – which might extend their market exclusivity to as much as 30 months.

Currently, patients who cannot afford or don’t have access to the drugs often resort to ready-made preparations that will not be FDA-approved, although their raw materials come from FDA-registered factories. Blaha has “a number of patients” who don’t have access to the brand-name drugs and are available to the clinic with vials of ready-made preparations.

Two weeks before Sanders published his letter in Denmark, Novo Nordisk cut the local price of Ozempic by 34 percent to $130 a month – about 15 percent of the U.S. list price. The government, which had threatened to stop covering the drug, agreed to cover the fee of Ozempic diabetes treatment, but just for patients who had previously tried a less expensive drug equivalent to metformin.

Wegovy, the identical weight-loss drug in higher doses, would must be paid for by the patient in just about all cases. The monthly cost is $365. That price, while moderate by U.S. standards, has sparked heated debate in regards to the unequal impact of social class on the affordability of the drug, says Nils Jakob Knudsen, an endocrinologist in Copenhagen.

Calculating drug prices is complex for the Danes, he added, because “the booming economy for Novo also drives our very healthy Danish economy.”

Novo Nordisk's market valuation of $591 billion on August 2 was significantly higher than Denmark's entire GDP.

---

©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.

Originally published: August 17, 2024 at 3:30 am

Latest technology in healthcare